Drug Trial Radar · NCT05743075
A Study to Evaluate the Efficacy and Safety of Ensifentrine for 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Last checked: Nov 20, 2026Latest source record: Jun 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
526
Actual
Start
Mar 10, 2023
Primary completion
Dec 6, 2024
Study completion Mar 7, 2025
Sponsor
- Lead sponsor
- Nuance Pharma (shanghai) Co., LtdIndustry
- Sponsor type
- Industry
- Collaborators
- Laboratory Corporation of America
- First posted
- Feb 24, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, randomized, double-blind, placebo-controlled, parallel-group clinical study, which aims to evaluate the efficacy, safety, and PK characteristics of Ensifentrine 3 mg twice daily (BID) for 24 weeks treatment of moderate to severe COPD.
Conditions
- Chronic Obstructive Pulmonary Disease
Interventions
EnsifentrineDrug
A dual PDE3/PDE 4 inhibitor
PlaceboDrug
Placebo solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Average forced expiratory volume in 1 second (FEV1) area under the curve (AUC)0-12hTime frame: 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
1st Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.